Provided is a molecular imprint polymer that is capable of acquiring stealth properties through a new mechanism. The molecular imprint polymer according to the present invention, which has a plasma protein recognition sites molecularly imprinted by a plasma protein thereon and contains a constituent derived from a biocompatible monomer, is an in vivo stealth nanoparticle to be used in intravascular delivery. As the plasma protein, albumin is preferred. When carrying a drug thereon, the in vivo stealth nanoparticle according to the present invention is usable as a drug for drug delivery system.

The present invention provides a non-viral polyplex particle for delivering nucleic acid to cells, comprising an effective amount of polyethylenimine complexed with an effective amount of the nucleic acid; and an effective amount of an anionic biomaterial that envelops the complexed acetylated polyethylenimine and nucleic acid.

N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.

Metastatic triple negative breast cancer (TNBC) still carries a dismal prognosis with the current treatment paradigms. The effectiveness of drug treatment for many solid tumors such as TNBC is limited by tumor heterogeneity, lack of tumor specificity, off-target toxicities, and transient therapeutic action(s). Strategies that provide tumor-specific, sustained concentrations of drugs to the tumors and tumor receptor-specific binding, while reducing off-target effects are needed to ensure sufficient tumor cell uptake within the primary and metastatic tumor microenvironment. The decreased non-specific adhesivity, receptor-targeted nanoparticle formulations (DART nanoparticles) of the invention were assessed for clinical potential in directing biological agents to the cell surface receptor Fn14, which is expressed in many solid cancer types, including TNBC primary tumors and metastatic lesions. They are contemplated for use against solid tumors, particularly brain tumors such as glioblastoma and breast cancer, including metastatic breast cancer.

The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).

Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moiety covalently bonded to the cyclic peptide moiety through a nitrogen atom of a side chain functional group of an internal residue of the cyclic peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and a nanoparticle active agent moiety covalently bonded to the cyclic peptide moiety, pharmaceutical compositions and uses thereof.

The present invention relates to nanospheres which comprise a polymeric matrix and antigen-binding molecules esterase-releasably incorporated therein and are coated with targeting molecules which increase the cellular uptake of the nanospheres. The polymeric matrix is formed by poly(alkyl cyanoacrylates) and/or alkoxy derivatives thereof. The invention further relates to methods for preparing and compositions comprising such nanospheres.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

A polymer-metal oxide complex, comprising a metal oxide particle located at the core and a polymer modified on the surface of the metal oxide particle, the polymer being provided with functional groups capable of bonding with a metal in the metal oxide, the density of the binding sites of the polymer and the surface of the metal oxide particle being greater than two sites/square nanometer. Also disclosed are a preparation method for the polymer-metal oxide complex, and applications of the polymer-metal oxide complex as a nuclear magnetic resonance contrast agent and as an iron supplement. The polymer-metal oxide complex has a significantly extended in vivo circulation time and effectively overcomes the defect that existing contrast agents cause hypersensitivity, which in addition to the superparamagnetic and iron metabolism participation functions of the complex, enables the complex to be applied as a magnetic resonance imaging contrast agent and as an iron supplement treating iron-deficiency anaemia.

The present invention provides nanoparticles comprising: (a) an amphiphilic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less; and (b) a peptide that is covalently linked to the polymer, wherein the peptide comprises 8 to 50 amino acids, including an N-terminal linker sequence comprising at least one Arg amino acid residue and a sequence comprising an MHC binding sequence comprising a T cell receptor epitope. The present invention further comprises compositions comprising respective nanoparticles and a liquid or lyophilized carrier as well as nanoparticles and compositions of the invention for use in inducing tolerance to a therapeutic compound (protein, viral vector, lipid vesicle), an allergen or to an autoantigen or for treating an allergy, an autoimmune disease, an exogenous antigen (transplantation antigens, drugs) or a food intolerance.